Background - Treatment of ovarian cancer remains very challenging, with 80-85% of the cases still dying after relapse to standard chemotherapy, and alternative treatments are urgently needed. Expansion of regulatory T cells (Tregs) is considered the major factor limiting spontaneous immune responses to ovarian cancer. Agonist antibodies against the co-stimulatory receptor OX40 have recently demonstrated to abrogate Treg functions and are under clinical evaluation. We thus studied whether OX40 constituted a valid target of ovarian cancer-associated Tregs. Methods -Treg immunophenotypic analyses were performed by flow cytometry in ascites and ovarian cancer specimens and studied in association with patients' outcome. Results - CD4+CD25+Foxp3+ Treg% and OX40 expression were measured in 50 diagnostic ovarian cancer cases (36, high grade serous carcinomas; 14, other histotypes). Treg% was significantly higher in ovary (47 evaluable cases) relative to ascites (39 evaluable cases) (p<0.0001). Treg % in ascites and peripheral blood from ovarian cancer patients or healthy donors were not significantly different. The fraction of Tregs expressing OX40, instead, dramatically increased from peripheral blood to ascites (p<0.01), and was even higher within the tumor (p<0.001). In 24 patients (stage IIC-IV; 19, high grade serous carcinoma; 5, other histotypes) with ≥12-month follow-up after surgery and carboplatin-paclitaxel, we analyzed OX40 expression on intratumor Tregs in function of the outcome. Patients with Treg% or OX40 MFI above the mean had a significantly reduced OS (p=0.004, p=0.02). Interestingly, having both high Treg% and OX40 MFI trended toward the worst OS, followed by high Treg% or OX40 MFI alone, whereas the lack of these parameters was associated with a significantly improved survival (mean: 28, 36, 41 and 53 months). OX40+ Tregs in both ascites and ovarian cancer tissue included CD45RA-, Foxp3hi, ICOS+ IFNγ- effector Tregs, thus indicating that OX40 may define a subset of highly suppressive Tregs in ovarian cancer. Conclusions - Our study underscores a negative prognostic impact of OX40 expression on ovarian cancer-infiltrating Tregs and indicates that OX40 may constitute a rational target to counteract effector Treg functions and unleash potentially effective immune responses against ovarian cancer. Citation Format: Massimo Di Nicola, Roberta Zappasodi, Alessia Burocci, Giusi Ruggiero, Fabio Martinelli, Claudio Tripodo, Domenica Lorusso, Filippo De Braud, Francesco Raspagliesi, Mario P. Colombo. OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B157.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.